Ontology highlight
ABSTRACT: Purpose
The aim of this study is to investigate the role of health-related quality-of-life (QoL) data in relative effectiveness assessments (REAs) of new anti-cancer drugs across European jurisdictions, during health technology assessment procedures.Methods
Comparative analysis of guidelines and publicly available REAs in six European jurisdictions of anti-cancer drugs approved by EMA between 2011 and 2013.Results
Fourteen anti-cancer drugs were included, adding up to 79 REAs. Whilst all guidelines state that QoL is a relevant endpoint to determine the relative effectiveness of new cancer drugs, QoL data were included in only 54% of the 79 reports and their impact on the recommendations was limited.Conclusions
Whilst national guidelines recognize the relevan
SUBMITTER: Kleijnen S
PROVIDER: S-EPMC5548837 | biostudies-literature | 2017 Sep
REPOSITORIES: biostudies-literature